Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 19;10:2964. doi: 10.1038/s41598-020-59746-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

TAE combined with iodized oil containing Apatinib can inhibit tumor growth in rabbit VX2 liver cancer model. (A) CT enhancement scan and DSA angiography aimed at liver cancer were performed on rabbits before and after intervention embolization treatment. We could see round tumor in the liver (black arrows), and that the blood-supply vessels in tumor were completely blocked after treatment. Gross specimens of the liver were taken 7 days after embolization, tumor was almost completely necrotic after embolization. (B) TAE combined with Apatinib can inhibit the growth of liver cancer. P = 0.022 < 0.05 versus NS group, P = 0.000 < 0.001 versus I group. (C) Apatinib inhibite HepG2 cell proliferation Data from the CCK-8 assays show the inhibition of HepG2 cell proliferation in response to treatment with different concentrations of Apatinib under normoxic and hypoxic conditions for 48 h. (D,E) The expression of VEGF and HIF-1α varied with time in each group of experimental rabbits. Each point represents the mean ± SD (n = 3). *P < 0.05, ***P < 0.001.